Home > Boards > US Listed > Biotechs > Compugen (CGEN)

Fair assessment but the pipeline is as strong

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
J.D. Penny Member Profile
 
Followed By 68
Posts 2,718
Boards Moderated 0
Alias Born 03/01/13
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 1/9/2020 7:10:18 AM
Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors GlobeNewswire Inc. - 12/12/2019 11:35:07 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/12/2019 7:09:34 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/5/2019 8:08:05 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/4/2019 7:15:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/19/2019 8:46:02 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/9/2019 6:16:44 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/6/2019 2:12:28 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/13/2019 6:01:04 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 8/5/2019 7:33:04 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/5/2019 7:02:05 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/2/2019 7:00:57 AM
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting PR Newswire (US) - 6/3/2019 7:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/30/2019 10:19:20 AM
Compugen to Present at the Jefferies 2019 Healthcare Conference PR Newswire (US) - 5/22/2019 7:00:00 AM
Compugen Reports First Quarter 2019 Results PR Newswire (US) - 5/20/2019 7:05:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2019 7:01:27 AM
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid ... PR Newswire (US) - 5/20/2019 7:00:00 AM
Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET PR Newswire (US) - 5/6/2019 7:00:00 AM
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting PR Newswire (US) - 4/3/2019 7:00:00 AM
Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed's Oral Insulin Capsules PR Newswire (US) - 3/26/2019 8:40:00 AM
Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management PR Newswire (US) - 3/26/2019 7:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/21/2019 6:43:17 AM
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate PR Newswire (US) - 3/12/2019 7:46:00 AM
Compugen to Present at the Cowen and Company 39th Annual Health Care Conference PR Newswire (US) - 3/5/2019 7:00:00 AM
J.D. Penny   Thursday, 11/07/19 01:55:02 PM
Re: CarlsJ post# 174
Post # of 176 
Fair assessment but the pipeline is as strong as ever and a lot of big pharma cant even come close to the propspects Compugen has. Nov 11 stands out as another big date for investors. Lets see how earnings or any other announcements prior to 2020 pan out.

$6.50 plus before end of the year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist